APBMT2010 Abstract

Autologous versus allogeneic hematopoietic stem cell transplantation (SCT) for peripheral T-cell lymphomas (PTCLs): Japan and Korea cooperative study with pathological central review

Sung-Won Kim1, Sung-Soo Yoon2, Ritsuro Suzuki3, Hyeon Gyu Yi4, Masahiro Imamura5, Atushi Wake6, Takashi Yoshida7, Je-Jung Lee8, Jin Seok Kim9, Yoshinobu Maeda10, Koji Izutsu6, Hye Jin Kang11, Ho Sup Lee12, Je-Hwan Lee13, Junji Suzumiya14, Yoshihiro Matsuno5, Chul Woo Kim2, Koji Nagafuji15, Takahiro Fukuda1, Kensei Tobinai1, Mine Harada16 and Chul Soo Kim4

1National Cancer Center Hospital, Tokyo, Japan; 2Seoul National University, Seoul, Korea; 3Nagoya University, Nagoya, Japan; 4Inha University, Incheon, Korea; 5Hokkaido University, Sapporo, Japan; 6Toranomon Hospital, Tokyo, Japan; 7Toyama Prefectural Central Hospital, Toyoma, Japan; 8Chonnam National University Hwasun Hospital, Hwasun, Korea; 9Yonsei University Severance Hospital, Seoul, Korea; 10Okayama University, Okayama, Japan; 11Korea Cancer Center Hospital, Seoul, Korea; 12Kosin University Gospel Hospital, Busan, Korea; 13University of Ulsan, Asan Medical Hospital, Seoul, Korea; 14Shimane University, Izumo, Japan; 15Kurume University, Kurume, Japan; 16National Hospital Organization, Oomuta Hospital, Oomuta, Japan

Background: To evaluate the role of auto- and allo-SCT in the treatment of PTCLs, Japan Study Group for Cell Therapy and Transplantation conducted a multicenter retrospective survey in Japan and Korea.

Methods: After excluding patients with ATLL and NK-cell tumors, patient data were newly collected from 330 patients who underwent SCT between 9/1991 and 12/2008. By pathological central review, 232 patients (135 autologous and 97 allogeneic including 26 patients with previous autograft) were eligible. There were 103 (44%) patients with PTCL-NOS, 67 (29%) with AITL, 28 (12%) with ALC (18 ALK-negative, 7 positive and 3 unknown), and others. Allo-SCT (37 BM, 44 PB, 1 BM+PB, 15 CB) was performed using a RIC in 59 patients (61%). The disease status at transplant in the allo-group was significantly worse than that in the auto-group.
**Results:** The NRM in the auto-group was significantly lower than that in the allo-group (P<0.0001). Grade II-IV acute GVHD occurred in 40% of the patients after allo-SCT. The long-term relapse rate in the auto-group was significantly higher than that in the allo-group (P=0.03). Early survival rate after transplant was significantly better for auto-group than allo-group (P=0.001), but the difference was marginal in the total course (P=0.06). Multivariate analyses showed that the risks of survival were age (>50 years), performance status at transplant (>1), stage at transplant (III-IV), but not transplant type (auto- versus allo-group). The survival of the patients with any disease status at transplant did not plateau in the auto-group, but the survival of the patients with CR1/PR1 and resistant relapse at transplant plateaued after day 250 in the allo-group (68% and 40%, respectively).

**Conclusions:** Despite a worse disease status at transplant in the allo-group, the overall survival was comparable to that in the auto-group. This supports the notion that early allo-SCT is a valuable treatment option for PTCLs.